絞り込み

16644

広告

子どもを早産 親どうしがアプリを使い交流 悩みなど相談 (NHK)

早産などで産まれた赤ちゃんの親どうしが、自宅にいながら交流できる機会をつくろうと、当事者たちがスマートフォンなどのアプリを使った対面式の交流会に取り組んでいます...

  1. 中国全土に新型肺炎広がる 春節祝賀行事を...
  2. 庁舎内のレジ袋削減へ実証実験 経産省など...
  3. iPS細胞で膝関節治療 京大・臨床研究計...
  4. [企業] RocheのPD-L1抗体テセ...

ニュース一覧

「elotuzumab」の検索結果

255件中 1件~20件表示    検索結果をPubMedで見る PubMedで見る

An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part II: limit of detection and follow-up of patients with small M-proteins.

An international multi-center serum protein electrophoresis accuracy and M-protein isotyping study. Part I: factors impacting limit of quantitation of serum protein electrophoresis.

APOBEC3B reporter myeloma cell lines identify DNA damage response pathways leading to APOBEC3B expression.

[Elotuzumab treatment for a multiple myeloma patient relapsing after allogenic stem cell transplantation].

Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma.

Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets.

Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma.

Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan.

Elotuzumab in combination with pomalidomide and dexamethasone for the treatment of multiple myeloma.

A Novel Approach to Remove Interference of Therapeutic Monoclonal Antibody with Serum Protein Electrophoresis.

[Management of multiple myeloma in the relapsed/refractory patient].

Activity of TAS4464, a novel NEDD8 activating enzyme E1 inhibitor, against multiple myeloma via inactivation of NF-κB pathways.

Advanced systemic mastocytosis with strong expression of signaling lymphocyte activation marker family member 7 (SLAMF7) responsive to therapy with elotuzumab and lenalidomide.

Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma.

Treatment of relapsed multiple myeloma: Evidence-based recommendations.

Enhanced SLAMF7 homotypic interactions by elotuzumab improves NK cell killing of multiple myeloma.

Monoclonal antibody utilization characteristics in patients with multiple myeloma.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
Sort by
※並べ替えは表示に時間がかかります